Experimental Lu AE58054 Drug Shows Promise and is Currently Being Investigated as a Treatment for Alzheimer's


Experimental Lu AE58054 Drug Shows Promise and is Currently Being Investigated as a Treatment for Alzheimer's

(Editor’s Note: The following article is part of a sponsorship program to create awareness for and participation in clinical trials for Alzheimer’s disease.)

One of the biggest problems we face in finding an effective treatment for Alzheimer’s is the lack of participation by qualified patients in clinical trials.


The benefits to the people living with Alzheimer’s are great when participating in a clinical trial. 

This includes not only testing to determine the stage of the disease but also medical testing to determine overall health. This study is testing an adjunctive therapy which allows your loved one to take the study drug with Donepezil (Aricept), Rivastigmine (Exelon) or Galantamine (Razadyne).

The phase II clinical trial highlighted here shows promise and could result in an effective drug for AD. Right now, the study is seeking qualified Alzheimer’s patients for its Phase III clinical trial. Could this be the one?

The phase III clinical trial (Star Studies) is now open and recruiting new patients. To learn if you loved one is qualified to participate for this clinical trial, go here or click on the image above.

The phase III study will have the following:

  • All study-related medicines and consultations specific to the study will be free of charge and reasonable travel, parking and food expenses will be paid

  • The patient may continue to see their regular doctor while participating in this study

  • Health insurance is not required to participate in this study

  • A high standard of study-related medical care will be provided

  • Patients may help to advance a potential new treatment for mild to moderate Alzheimer’s disease

  • Patient may have an opportunity to continue in a six-month extension

The successful Phase II clinical data for Lu AE58054 showed statistically significant improvement as an add on to donepezil (Aricept) on cognitive symptoms of Alzheimer’s disease.


  • Lu AE58054 is a selective 5-HT6 receptor antagonist under investigation for the treatment of Alzheimer's disease. This is an experimental drug that is now being tested in a Phase III clinical trial.

  • The5-HT6 receptor is a different approach from the amyloid and tau hypotheses that have underpinned much of the research to date on Alzheimer’s disease.

  • The phase II clinical study demonstrated that treatment with Lu AE58054 and donepezil (Aricept) for six months improved cognitive performance in patients with moderate Alzheimer’s disease.

Source of information and to learn more about the Phase II clinical trial--http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=796082

This article originally appeared on Alzheimer’s Reading Room

Like this article? Share on social